| Micro-channel |
 |
|
|
|
|
|
| |
| The "circuit" of the cardiovascular health industry |
| |
| Author：中國銘鉉 企劃部 Release Time：2017-9-12 12:04:11 Number Browse：901 |
| |
On September 12, in the context of the state's encouraging development of the health industry, all the capital is speeding up the big health "cake". Sponsored by the CHC medical advice before in the 4th China CEO on the BBS, cardiovascular health industry investment and m&a from blue mountain capital, qiming, co-win, step length pharmaceutical, xinli ty PE/VC and the representative of the listed company, on cardiovascular health industry innovation and investment opportunity brainstorming. The personage inside course of study is generally believed that in technology innovation, under the drive of cardiovascular industry in China is in rapid growth, cardiovascular interventional devices, drug use and the service sector will benefit from the innovation drive and usher in a huge space for development, industry capital investment in the field of cardiovascular mergers and acquisitions are moving in the climax.
According to the national center for cardiovascular disease cardiovascular disease report 2016 of the People's Republic of China, cardiovascular disease prevalence in the rising stage in our country, the existing cardiovascular disease patients of about 290 million, more than one 5 of the total population.
The continued rise in cardiovascular disease has increased clinical demand, and associated medical costs have been growing in double digits for years. In the view of liu dazhi, founder and managing partner of mountain blue capital, technological innovation is an important engine driving the rapid development of cardiovascular industry. Currently, the most closely watched cardiovascular intervention, heart valve intervention, heart failure, peripheral vascular intervention, neurointerventional and other subdivisions are all benefiting from the rapid development of technological innovation.
It is understood that compared with the growth rate of 4% in the international market, the growth rate of these segments is at least 10% in China. Among them, the interventional operation of coronary heart disease in 2016 increased by 17.4%, pacemaker implantation increased 11%, ICD implant increased by 18%, cardiac arrhythmia catheter ablation increased 30%, CRT increased 15%. Liu Daozhi argues that, in the next five to 10 years, as peripheral vascular interventional devices, valve equipment, electrophysiological ablation instrument, nerve interventional devices such as segments are likely to grow to the scale of the global sales of 5 billion yuan of above. It is foreseeable that the cardiovascular industry has great growth potential in China.
The high growth of cardiovascular industry has attracted the attention of industrial capital. A number of listed companies, such as lep medical, step pharma and xin litai, have been cutting through cardiovascular disease, medical devices and services, and constantly improving the layout of the cardiovascular industry chain. Among them, lep medical has been around the medical device, medicine, medical service and mobile medical treatment, becoming the domestic cardiovascular whole industry chain platform type enterprise. Last year listed step pharmaceutical is give full play to the important role in the field of traditional Chinese medicine in heart cerebrovascular drugs, developed heart failure capsule, metacentric particles and Dan red injection three exclusive varieties, treatment of stroke and range, arrhythmia, insufficient blood supply and ischemic infarction and other common disease of heart head blood-vessel. In the first half of 2017, the company's four core products, the brainheart capsule, the metacentric granule, the danhong injection, the combined income of gu hong injection reached 42.14 billion yuan. Zhao tao, chairman of the company's pharmaceutical company, also expressed a positive view of cardiovascular medicine on BBS.
In terms of market segmentation, cardiovascular intervention equipment is generally favored by investors. To lead the trend in this segment, liu said, there must be a revolutionary product to support it. In addition, some new product areas should be laid out, including drug eluting peripheral vascular stents, neuro-interventional instruments, and interventional valves.
International medical technology companies like medtronic are more optimistic. "The area of heart failure, whether it's a variety of interventions or neuroregulation, is not yet a really mature project or a clinically disruptive technology, and that's one area we're looking at." "Said cheng lifei, vice President of medtronic greater China.
The new catheter ablation products and new technology in the heart valve and electrophysiology are promising.
In addition to the cardiovascular medicine and medical devices driven by technological innovation, the business model innovation also opened up the market for cardiovascular medical services. The personage inside course of study thinks, the current group of cardiologists and cardiovascular specialist hospital rapid development in China, it is health care reform, doctors free practice such as policy innovation opportunities brought by the dividends to the medical services.
|
| |
Previous article：Jiangxi: by 2020, all medical institutions will be covered by disease
Next article：The development of original drug in hubei has exploded and the generic drug is evenly split
|
| |
|
|
